The subscription period of the series TO 1 warrants starts today
Stem cell company NextCell Pharma AB ("NXTCL") announces that today, 23rd of August 2018, marks the start of the subscription period of the series of TO 1 series warrants which were issued as part of the company's issue of units during the spring of 2017. The subscription period will end on the 13th of September 2018. Holders of the series TO 1 warrants are entitled to subscribe for a new share for each warrant at a price of SEK 5.00 per share. If all of the series TO 1 warrants are exercised, 2 860 940 new shares will be issued and NXTCL is receives approximately MSEK 14.3 before issue costs.
Summary terms for series TO 1 warrants
Subscription period: 23rd August – 13th September 2018.
Issue volume: 2 860 940 of series TO 1 warrants. At full utilization, 2 860 940 shares will be issued and will contribute approximately MSEK 14.3 to NXTCL before issue costs.
Strike price: SEK 5.00 per share.
Last day of trading with the warrants: 11th September 2018.
Valuation according to the current offer (pre-money): Approximately MSEK 42.5.
Market value: About MSEK 59.5.
The full terms for the series TO 1 warrants, teaser and subscription form are available on the NXTCL website (www.nextcellpharma.com). The Teaser and subscription form are also available on the websites of; Sedermera Fondkommissions (www.sedermera.se) and Spotlight Stock Markets (www.spotlightstockmarket.com).
Important dates during the subscription period of the series of TO 1 series warrants
Start of subscription period: 23rd August 2018.
Last day of trading with the warrants: 11th September 2018.
End of subscription period: 13th September 2018.
Payment: Cash payment no later than 15:00 on 13th September 2018.
Scheduled communication of outcome: Week 38.
Scheduled conversion of interim shares to shares: Week 41.
Do you have your nominee registered warrants?
In the event that the warrant holder has his or her warrants held in a custody account, in an investment savings account or in a capital insurance account (nominee-registered ownership), subscription/payment shall be made to the respective trustee who can provide further instructions regarding the procedures for exercising the warrants. During the subscription period of the warrants (23rd August 2018 through 13th September 2018), it is possible to convert from warrants to interim shares. For further information and instructions on how to proceed to exercise your warrants, please contact your trustee in good time. Please note that the bank/trustees need your application stating you wish to exercise your series TO 1 warrants in good time before the end of the subscription period.
Do you have your warrants directly registered?
No emission report will be sent. Application forms are available on the websites of: Spotlight Stock Markets (www.spotlightstockmarket.com), Sedermera Fondkommissions (www.sedermera.se) and NextCell Pharma AB (www.nextcellpharma.com).
When the application form is submitted to Sedermera Fondkommission, payment needs to be made in accordance with payment instructions on the application/subscription form. During the subscription period of the warrants which runs from 23th August to 13th September, it is possible to convert from warrants to interim shares, provided that the application form and payment are received by Sedermera Fondkommission no later than the date stated on the application form. As soon as both subscription and payment have been registered with Sedermera Fondkommission, the warrants are replaced by interim shares pending registration with the Swedish Companies Registration Office. Subsequently, interim shares are replaced by shares.
Note that the series TO 1 warrants expire at no value if the holder does not actively subscribe for shares by 13th September 2018 or sells the warrants by 11th September 2018.
Financial adviser and issuing agent
Sedermera Fondkommission is the financial advisor to NXTCL for the subscription period of the series TO 1 warrants.
For more information regarding the subscription of series TO 1 warrants, please contact:
Sedermera Fondkommission
Phone: 040-615 14 10
E-mail: info@sedermera.se
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Leo Groenewegen, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
About NextCell Pharma AB:
Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.